Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Underwriter’s Over-allotment Option
October 22, 2021 16:05 ET
|
Context Therapeutics
PHILADELPHIA, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (the “Company”) (Nasdaq: CNTX), a women’s oncology company developing advanced small molecule and immunotherapy treatments...
Context Therapeutics® Announces Pricing of Initial Public Offering
October 19, 2021 19:14 ET
|
Context Therapeutics
PHILADELPHIA, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (the “Company”) (Nasdaq: CNTX), a women’s oncology company developing advanced small molecule and immunotherapy treatments...
Context Therapeutics® and Tyligand Bioscience Reach ONA-XR Manufacturing Optimization Milestone
August 25, 2021 08:00 ET
|
Context Therapeutics
PHILADELPHIA and SHANGHAI, China, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (the “Company”), a women’s oncology company developing advanced small molecule and immunotherapy...
Context Therapeutics® and Jefferson Health Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Advanced Endometrial Cancer
May 12, 2021 08:00 ET
|
Context Therapeutics
PHILADELPHIA, May 12, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics, a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven...
Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6 Antibodies for Gynecologic Cancer Therapeutic Program
April 08, 2021 08:00 ET
|
Context Therapeutics
PHILADELPHIA, April 08, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics, a clinical-stage women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for...
Context Therapeutics® Expands Board of Directors
March 22, 2021 08:00 ET
|
Context Therapeutics
-- Company Adds Richard Berman, Jennifer Evans Stacey and Linda West to Board -- -- Appointments Bolster Business and Clinical Development and Commercial Strategy Expertise as Context Prepares to...